Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07197788) titled 'Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study' on Sept. 26.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Endogenex, Inc.
Condition:
Type 2 Diabetes Mellitus
Type2diabetes
Diabetes Mellitus, Type 2
Type 2 Diabetes
Diabetes
Intervention:
Device: Endogenex System
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: October 2025
Target Sample Size: 50
To know more, visit https://clinicaltrials.gov/study/NCT07197788
Publ...